Monoclonal antibodies as inhibitors of PD1 and PD-L1 are being tested in trials concerning patients with recurrent GBM (Table 1) [111,112,113,114,115,116,117,118,119,120]. The gene discussed is PDCD1; the disease is glioblastoma.